Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 1647 | 7.1466 |
09:39 ET | 200 | 7.1594 |
09:41 ET | 100 | 7.095 |
09:43 ET | 600 | 7.1506 |
09:48 ET | 100 | 7.03 |
09:56 ET | 400 | 7.085 |
10:01 ET | 100 | 7.05 |
10:03 ET | 106 | 7.05 |
10:06 ET | 813 | 7.02 |
10:08 ET | 3724 | 7.0304 |
10:10 ET | 3200 | 7.005 |
10:12 ET | 481 | 6.9715 |
10:15 ET | 1814 | 6.96 |
10:17 ET | 600 | 6.94 |
10:26 ET | 600 | 6.91 |
10:28 ET | 1100 | 6.87 |
10:30 ET | 440 | 6.915 |
10:32 ET | 200 | 6.94 |
10:33 ET | 600 | 6.87 |
10:35 ET | 710 | 6.92 |
10:39 ET | 300 | 6.9 |
10:42 ET | 600 | 6.96 |
10:44 ET | 505 | 6.975 |
10:48 ET | 100 | 7.01 |
10:50 ET | 200 | 7.02 |
10:51 ET | 200 | 7.02 |
10:55 ET | 700 | 6.99 |
10:57 ET | 859 | 6.98 |
11:00 ET | 343 | 6.92 |
11:04 ET | 100 | 6.92 |
11:06 ET | 100 | 6.9 |
11:09 ET | 300 | 6.925 |
11:11 ET | 100 | 6.9 |
11:13 ET | 100 | 6.89 |
11:18 ET | 995 | 6.95 |
11:27 ET | 100 | 6.935 |
11:31 ET | 100 | 6.96 |
11:36 ET | 658 | 6.96 |
11:38 ET | 900 | 6.9698 |
11:44 ET | 100 | 6.955 |
11:45 ET | 1780 | 6.935 |
11:49 ET | 300 | 6.9175 |
11:54 ET | 490 | 6.91 |
11:56 ET | 319 | 6.89 |
12:00 ET | 100 | 6.86 |
12:02 ET | 4101 | 6.86 |
12:03 ET | 100 | 6.845 |
12:07 ET | 100 | 6.845 |
12:09 ET | 697 | 6.82 |
12:14 ET | 100 | 6.835 |
12:20 ET | 398 | 6.8219 |
12:21 ET | 100 | 6.82 |
12:23 ET | 3356 | 6.87 |
12:30 ET | 161 | 6.84 |
12:32 ET | 637 | 6.81 |
12:34 ET | 1183 | 6.83 |
12:36 ET | 146 | 6.79 |
12:41 ET | 251 | 6.78 |
12:43 ET | 200 | 6.78 |
12:45 ET | 100 | 6.7758 |
12:48 ET | 200 | 6.76 |
12:50 ET | 200 | 6.78 |
12:57 ET | 700 | 6.8 |
12:59 ET | 100 | 6.8 |
01:01 ET | 300 | 6.785 |
01:03 ET | 1226 | 6.78 |
01:06 ET | 800 | 6.8 |
01:08 ET | 100 | 6.795 |
01:10 ET | 100 | 6.79 |
01:12 ET | 400 | 6.79 |
01:15 ET | 100 | 6.79 |
01:17 ET | 200 | 6.8 |
01:19 ET | 117 | 6.81 |
01:21 ET | 300 | 6.81 |
01:26 ET | 200 | 6.825 |
01:28 ET | 200 | 6.82 |
01:30 ET | 100 | 6.84 |
01:32 ET | 300 | 6.81 |
01:33 ET | 200 | 6.8025 |
01:35 ET | 200 | 6.81 |
01:37 ET | 100 | 6.82 |
01:39 ET | 200 | 6.81 |
01:44 ET | 100 | 6.815 |
01:46 ET | 262 | 6.84 |
01:48 ET | 400 | 6.83 |
01:50 ET | 100 | 6.8 |
01:53 ET | 147 | 6.8 |
01:55 ET | 300 | 6.8 |
01:57 ET | 700 | 6.84 |
02:00 ET | 100 | 6.825 |
02:06 ET | 863 | 6.83 |
02:08 ET | 1050 | 6.795 |
02:13 ET | 389 | 6.805 |
02:15 ET | 200 | 6.805 |
02:18 ET | 100 | 6.8 |
02:20 ET | 700 | 6.8 |
02:22 ET | 100 | 6.82 |
02:24 ET | 200 | 6.805 |
02:26 ET | 6951 | 6.83 |
02:27 ET | 12567 | 6.81 |
02:31 ET | 400 | 6.8 |
02:33 ET | 800 | 6.8 |
02:36 ET | 2031 | 6.8 |
02:42 ET | 514 | 6.7975 |
02:45 ET | 808 | 6.81 |
02:49 ET | 300 | 6.82 |
02:54 ET | 300 | 6.83 |
02:58 ET | 100 | 6.84 |
03:00 ET | 300 | 6.84 |
03:02 ET | 249 | 6.86 |
03:03 ET | 100 | 6.84 |
03:05 ET | 374 | 6.84 |
03:07 ET | 773 | 6.85 |
03:09 ET | 1008 | 6.83 |
03:12 ET | 100 | 6.84 |
03:14 ET | 400 | 6.82 |
03:16 ET | 100 | 6.815 |
03:18 ET | 400 | 6.82 |
03:20 ET | 300 | 6.84 |
03:21 ET | 134 | 6.84 |
03:23 ET | 100 | 6.84 |
03:27 ET | 204 | 6.84 |
03:30 ET | 900 | 6.81 |
03:34 ET | 161 | 6.82 |
03:36 ET | 100 | 6.83 |
03:38 ET | 200 | 6.82 |
03:39 ET | 418 | 6.82 |
03:41 ET | 1205 | 6.83 |
03:43 ET | 500 | 6.83 |
03:45 ET | 200 | 6.84 |
03:50 ET | 700 | 6.84 |
03:52 ET | 985 | 6.89 |
03:54 ET | 400 | 6.89 |
03:56 ET | 1905 | 6.89 |
03:57 ET | 400 | 6.88 |
03:59 ET | 41991 | 6.89 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 148.0M | -0.7x | --- |
Adlai Nortye Ltd | 134.3M | -0.5x | --- |
Elevation Oncology Inc | 147.5M | -2.8x | --- |
Vigil Neuroscience Inc | 148.5M | -1.9x | --- |
Atossa Therapeutics Inc | 147.1M | -4.6x | --- |
bluebird bio Inc | 174.0M | -1.2x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $148.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.